Jason Hope Offers Hope to People with Parkinson’s and Other Degenerative Diseases
Stem cells have been in the news. They have been touted as a method to fight diseases, but some groups and organizations protested their existence; even so, several biotech companies are taking advantage of stem cells right now. Jason Hope witnessed that technology is advancing and that medicine has been a part of it. He believes that stem cells are going to continue to be in the spotlight in the future and beyond.
It was approximately 20 years ago that scientists began to extract embryonic stem cells from human beings, and they caused these cells to multiply in the lab, Jason Hope explains. Within the stem cell research field, these “parent cells” made it possible for the body to grow new cells, and it promised a way of developing regenerative treatments for Parkinson’s disease, stroke, Alzheimer’s and heart disease among other conditions.
Scientists believed that regenerative parent cells could also regenerate undesired cells so that the subject could experience anti-aging effects. It could also offer solutions for degenerative conditions that cause the body to deteriorate over time.
Jason Hope is a philanthropist, and he has been contributing to the medical industry and stem cell research. He is aware that the public has grown weary of some of the claims that several companies have been making about treatments that do not have sufficient evidence to show that they work. The business mogul does not share these people’s concerns because he is enthusiastic about stem cells, but he is willing to encourage long-term research in this area (Crunchbase).
Jason has been associated with the Strategies for Engineered Negligible Senescence or SENS Organization where he offered donations to the organization’s cause. Currently, the activist investor Jason Hope´s donations help scientists research preventative treatments for degenerative diseases. He is also involved in improving the quality of life for people with these types of diseases. Jason states that the clinical trials for stem cell treatment for patients with Parkinson’s disease are currently in the second stage.